OraSure Technologies (NASDAQ:OSUR) Releases Earnings Results, Misses Expectations By $0.05 EPS

OraSure Technologies (NASDAQ:OSUR) announced its quarterly earnings results on Tuesday. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.05), Zacks reports. OraSure Technologies had a net margin of 5.07% and a return on equity of 3.55%.

OraSure Technologies Stock Up 0.3 %

Shares of NASDAQ:OSUR traded up $0.01 during midday trading on Tuesday, reaching $4.00. The company’s stock had a trading volume of 773,708 shares, compared to its average volume of 810,212. The firm has a 50 day moving average of $3.80 and a 200-day moving average of $4.02. The firm has a market capitalization of $298.38 million, a P/E ratio of 26.67 and a beta of 0.05. OraSure Technologies has a 12-month low of $3.52 and a 12-month high of $8.04.

Analysts Set New Price Targets

Separately, StockNews.com cut OraSure Technologies from a “buy” rating to a “hold” rating in a research report on Saturday.

OraSure Technologies Company Profile

OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company’s products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.